The global protein A resin market is expected to increase at a y-o-y growth rate of over 7% and reach US$ 380.4 Mn in revenues in 2016. North America, Asia Pacific excluding Japan (APEJ), and Western Europe will collectively account for nearly 70% revenue share of the market in 2016. Increasing process efficiency, growing preference for e-distribution channels and strategic integration of supply chains are some of the major trends impacting the growth of the global protein A resin market.
The wide range of therapeutic applications of monoclonal antibodies will lead to more research and improved focus on biotechnology sector, resulting into increasing demand for protein A resins. Favourable government policies – in terms of formulation of suitable policies for startups and administration of funding for development of next-gen medical products — are expected to play an important role in driving growth. Development of cost-effective protein A resin is also expected to boost the growth of the market in 2016 and beyond. In contrast, efficacy of alternate purification methods of monoclonal antibodies and high cost (US$ 15,000 – US$ 16,000 per litre) will continue to pose challenges for widespread adoption.
Increasing number of clinical trials on biologics will continue to have a positive impact on protein A resins market in North America. The demand for protein A resins in APEJ region is expected to increase due to growing research on monoclonal antibodies in India and China.
General Electric Company and Thermo Fisher Scientific Inc. are among the leading players in the global protein A resin market. Emerging players Merck Millipore and REPLIGEN CORP., are focusing on increasing market share by strategic collaborations, while expansion of product portfolio in life science and research catalogues remains a key business strategy for Novasep and GenScript.
Report Overview, with TOC @ https://www.futuremarketinsights.com/reports/protein-a-resins-market/toc